BR112013025908A2 - preparações oftálmicas baseadas em pacap (polipeptídeo hipofisário ativador da adenilato ciclase) que recuperam a função visual normal em glaucoma inicial - Google Patents

preparações oftálmicas baseadas em pacap (polipeptídeo hipofisário ativador da adenilato ciclase) que recuperam a função visual normal em glaucoma inicial

Info

Publication number
BR112013025908A2
BR112013025908A2 BR112013025908A BR112013025908A BR112013025908A2 BR 112013025908 A2 BR112013025908 A2 BR 112013025908A2 BR 112013025908 A BR112013025908 A BR 112013025908A BR 112013025908 A BR112013025908 A BR 112013025908A BR 112013025908 A2 BR112013025908 A2 BR 112013025908A2
Authority
BR
Brazil
Prior art keywords
pacap
adenylate cyclase
visual function
glaucoma
cyclase activating
Prior art date
Application number
BR112013025908A
Other languages
English (en)
Inventor
Luca Giovannini
Luciano Domenici
Marco Sanso
Original Assignee
Hmfra Hungary Ltd Liability Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hmfra Hungary Ltd Liability Company filed Critical Hmfra Hungary Ltd Liability Company
Publication of BR112013025908A2 publication Critical patent/BR112013025908A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

preparações oftálmicas baseadas em pacap (polipeptídeo hipofisário ativador de adenilato ciclase) que recuperam a função visual normal em glaucoma inicial a presente invenção refere-se a preparações oftálmicas na forma de colírio baseadas em pacap (polipeptídeo hipofisário ativador de adenilato ciclase) que restauram a função visual normal em distrofia da retina/retinopatia e neuropatia óptica, com especial referência a glaucoma. as referidas preparações podem ser administradas por via tópica na superfície do olho intato, e são úteis no tratamento de várias formas de distrofia da retina/retinopatia e neuropatia óptica, tal como glaucoma.
BR112013025908A 2011-04-08 2012-04-05 preparações oftálmicas baseadas em pacap (polipeptídeo hipofisário ativador da adenilato ciclase) que recuperam a função visual normal em glaucoma inicial BR112013025908A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000583A ITMI20110583A1 (it) 2011-04-08 2011-04-08 Preparazioni oftalmiche a base di pacap (pituitary adenylate cyclase activating polypeptide) al fine di ripristinare la normale funzione visiva nel glaucoma in fase precoce
PCT/EP2012/001514 WO2012136369A1 (en) 2011-04-08 2012-04-05 Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma

Publications (1)

Publication Number Publication Date
BR112013025908A2 true BR112013025908A2 (pt) 2016-12-20

Family

ID=44553939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025908A BR112013025908A2 (pt) 2011-04-08 2012-04-05 preparações oftálmicas baseadas em pacap (polipeptídeo hipofisário ativador da adenilato ciclase) que recuperam a função visual normal em glaucoma inicial

Country Status (11)

Country Link
US (1) US20140315811A1 (pt)
EP (1) EP2694034A1 (pt)
JP (1) JP2014510115A (pt)
KR (1) KR20140041459A (pt)
CN (1) CN103501763A (pt)
BR (1) BR112013025908A2 (pt)
CA (1) CA2832486A1 (pt)
IT (1) ITMI20110583A1 (pt)
MX (1) MX2013011684A (pt)
RU (1) RU2013149171A (pt)
WO (1) WO2012136369A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821333A (zh) * 2015-07-13 2020-10-27 东北泰克诺亚奇股份有限公司 视神经保护用组合物
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
EP3974027A4 (en) * 2019-05-14 2023-08-16 Senju Pharmaceutical Co., Ltd. STABILIZED PACAP PEPTIDE
WO2022156373A1 (zh) * 2021-01-22 2022-07-28 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009318A1 (en) 1994-09-22 1996-03-28 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
CA2485216A1 (en) 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
MXPA06012175A (es) * 2004-04-23 2007-03-28 Senju Pharma Co Promotor de neuritogenesis corneal que contiene polipeptido activador de la adenilato ciclasa de la pituitaria y sus derivados.
JP2006306770A (ja) * 2005-04-27 2006-11-09 Nidek Co Ltd 眼疾患治療剤
JP2009269818A (ja) 2006-08-22 2009-11-19 Univ Showa Ｐａｃａｐペプチドを含む眼科用剤

Also Published As

Publication number Publication date
JP2014510115A (ja) 2014-04-24
RU2013149171A (ru) 2015-05-20
WO2012136369A8 (en) 2013-11-14
US20140315811A1 (en) 2014-10-23
CN103501763A (zh) 2014-01-08
CA2832486A1 (en) 2012-10-11
EP2694034A1 (en) 2014-02-12
KR20140041459A (ko) 2014-04-04
ITMI20110583A1 (it) 2012-10-09
WO2012136369A1 (en) 2012-10-11
MX2013011684A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
WO2016172712A3 (en) Ophthalmic composition
BR112017024531A2 (pt) lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir)
TW201613588A (en) Ophthalmic composition
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MX2019004468A (es) Uso de lentes de contacto en el tratamiento de una afeccion oftalmologica.
BR112014032897A2 (pt) métodos e aparelho para formar baterias impressas em dispositivos oftálmicos
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
BR112013025908A2 (pt) preparações oftálmicas baseadas em pacap (polipeptídeo hipofisário ativador da adenilato ciclase) que recuperam a função visual normal em glaucoma inicial
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
BR112014007439A2 (pt) método para projetar lentes de contato não esféricas macias
BR112013017875A2 (pt) introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
UY31785A1 (es) Sistema polimerico de lagrimas artificiales
MX2009010988A (es) Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
CO2017001454A2 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
AU2017248071A1 (en) Glasses provided with a light source, system comprising such glasses and a glasses case for such glasses
BR112013033355A2 (pt) sistemas de lente para presbiopia
AU2019283995A1 (en) Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
WO2014161004A3 (en) Compositions and methods for the delivery of drugs to the ocular surface by contact lenses
UY35307A (es) Composición antifúngica tópica para el tratamiento de onicomicosis
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
BR112015015853A2 (pt) lente oftálmica multifocal

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]